4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the third quarter ended September 30, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "We are pleased to report accelerating enrollment of our pivotal Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T). As of today, we have enrolled 32

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial of the company's lead asset, EryDex (intra-erythrocyte dexamethasone sodium phosphate), for the treatment of Ataxia-Telangiectasia (A-T). Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "We continue to gain valuable insights from the robust datas

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd Child Neurology Society (CNS) Annual Meeting of safety data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial. The objective of the data analysis was to evaluate treatment-emergent adverse events (TEAEs) in patients with Ataxia-Telangiectasia (A-T) treated with the company's lead asset, EryDex (intra-erythrocyte dexamethasone sodium phosphate), for one year compared to placebo control. Key find

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences: 2024 Maxim Healthcare Virtual Summit – Quince's Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., will participate in a fireside chat on Thursday, October 17, 2024 beginning at 3:00 p.m. Eastern Time. Qualified investors can register here to access the live event. LD Micro Main Event XVII – Quince's Chief Operating Officer and Chief Business Officer Brendan Hannah will present a company overview on Tuesday, October 29

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 beginning at 7 a.m. Eastern Time. A webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. About Quince Therapeutics Quince Therapeutics (NASDAQ:QNCX) is a late-stage biotechnology company dedicated to unlocking the power o

Findings from largest completed study in A-T demonstrated favorable safety profile Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age range that typically experiences rapid clinical decline Quince recently initiated pivotal Phase 3 NEAT study, which is currently enrolling and being conducted under U.S. FDA Special Protocol Assessment agreement Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the online publication of data in The Lancet Neurology from its Phase 3 ATTeST (Ataxia-Telangiectasia

Strong cash position expected to provide sufficient operating runway into 2026; Phase 3 topline results expected in the fourth quarter of 2025 Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the second quarter ended June 30, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "We achieved a major clinical milestone during the second quarter of 2024 with the first patient enrolled in our pivotal Phase 3 NEAT clinical trial in Ataxia-

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that the first patient has been dosed in the company's Phase 3 NEAT (Neurologic Effects of EryDex on Subjects with A-T) clinical trial to evaluate the neurological effects of EryDex in patients with Ataxia-Telangiectasia (A-T). This pivotal Phase 3 study will be conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food & Drug Administration (FDA). "The initiation of our pivotal Phase 3 NEAT study is a major milestone for Quince, and an opportuni

Fast Track designation underscores the high unmet medical need, with currently no approved therapeutic treatments for the rare pediatric disease Ataxia-Telangiectasia Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its EryDex System for the treatment of patients with Ataxia-Telangiectasia (A-T). EryDex is comprised of dexamethasone sodium phosphate (DSP) encapsulated in a patient's own red blood cells utilizing Quince's propriet

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today provided an update on the company's development pipeline and reported financial results for the first quarter ended March 31, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "Our primary corporate objective is the advancement of our lead asset, EryDex, for the treatment of patients with ataxia-telangiectasia. We remain on track to begin enrollment of our pivotal Phase 3 study in the second quarter of 2024 and will diligently pursue enrol

Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)

ARS - Quince Therapeutics, Inc. (0001662774) (Filer)

DEFA14A - Quince Therapeutics, Inc. (0001662774) (Filer)

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today provided an update on the company's development pipeline and reported financial results for the first quarter ended March 31, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "Our primary corporate objective is the advancement of our lead asset, EryDex, for the treatment of patients with ataxia-telangiectasia. We remain on track to begin enrollment of our pivotal Phase 3 study in the second quarter of 2024 and will diligently pursue enrollm

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.21) per share. This is a 61.54 percent decrease over losses of $(0.13) per share from the same period last year.

Strong Cash Position Expected to Support Meaningful Clinical Milestone Reported $75.1 million in cash, cash equivalents, and short-term investments as of December 31, 2023. Quince expects its existing cash runway to be sufficient to fund the company's capital efficient development plan into 2026. Expect to fully fund lead asset, EryDex, through Phase 3 NEAT topline results and prepare for a potential NDA submission in 2026, assuming positive study results. This includes approximately $20 million for the NEAT study and approximately $15 million in direct trial costs for the open label extension. Evaluate potential strategic partnerships to out-license ex-U.S. regional territories t

-SEC Filing

The Dow Jones closed higher by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. SHF Holdings The Trade: SHF Holdings, Inc. (NASDAQ:SHFS) Chief Legal Officer Donald Emmi acquired a total of 66,000 shares an average price of $0.87. To acquire these shares, it cost around $57,420. The company’s CEO also bought 20,000 shares of the c

The Dow Jones closed higher by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Vintage Wine Estates The Trade: Vintage Wine Estates, Inc. (NASDAQ:VWE) Director Timothy Proctor acquired a total of 31,852 shares an average price of $0.57. To acquire these shares, it cost around $18,155. What’s Happening: On Nov. 14, Vintage Wine

Gainers RVL Pharmaceuticals plc (NASDAQ:RVLP) shares rose 181.8% to $0.2201 in pre-market trading. Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares rose 86% to $0.3739 in pre-market trading. Novo Integrated Sciences and Blacksheep Trust signed a One Billion Dollar Master Collateral Transfer Agreement for the purpose and general use of monetization by Novo for a period of up to 15 years. Polished.com Inc. (NYSE:POL) shares surged 35% to $0.1060 in pre-market trading. Polished.com plans to hold a special meeting of stockholders to approve reverse stock split. OpGen, Inc. (NASDAQ:OPGN) shares gained 34.3% to $0.27 in pre-market trading. Brooge Energy Limited (NASDAQ:BROG) shares rose 2

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company's Board of Directors. "We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni's caliber to our Board of Directors," said David Lamond, chairperson of Quince's Board of Directors. "With expertise that spans the continuum from translational to registrational studies and regulatory agency negotiation in several rare diseases, we lo

Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company's corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.p.A., the international integration of financial and operational activities and ongoing business operations of Quince. Dirk Thye, M.D., Quince's Chief Executive Officer, said, "Charles is a valuable addition to our management team. His considera